+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Erectile Dysfunction Drugs Market by Treatment Duration, Dosage Strength, Patient Age Group, Drug Type, Mode of Administration, Distribution Channel - Global Forecast 2026-2032- Product Image
Erectile Dysfunction Drugs Market by Treatment Duration, Dosage Strength, Patient Age Group, Drug Type, Mode of Administration, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Erectile Dysfunction Drugs Market by Treatment Duration, Dosage Strength, Patient Age Group, Drug Type, Mode of Administration, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4989691
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Erectile Dysfunction Drugs Market is projected to reach USD 2.93 Billion in 2026. It is expected to continue growing at a CAGR of 7.82%, reaching USD 4.67 Billion by 2032.

The erectile dysfunction drugs market is anchored by a well-established clinical need: erectile dysfunction (ED) is strongly associated with age, diabetes, hypertension, cardiovascular disease, obesity, smoking, depression, prostate surgery, and medication-related adverse effects. Because ED can also be an early marker of vascular disease, demand for evidence-based ED treatment continues to expand across urology, primary care, men’s health clinics, digital health platforms, and retail pharmacy channels.

Phosphodiesterase type 5 inhibitors, including sildenafil, tadalafil, vardenafil, and avanafil, remain the dominant pharmacological class because major clinical guidelines recognize them as first-line oral therapy for many men with ED when contraindications, especially nitrate use, are excluded. Category development is being shaped by generic availability, telehealth prescribing, pharmacy-led access models, broader sexual wellness awareness, and the rising burden of metabolic and cardiovascular conditions that increase ED prevalence.

Transformative Shifts in the ED Treatment Landscape

The landscape is shifting from a specialist-led, stigma-constrained category to a more accessible, consumer-aware, and digitally enabled men’s health market. Generic sildenafil and tadalafil have intensified price competition while expanding patient access, especially in markets where payers and consumers prioritize affordability. Branded differentiation is increasingly tied to onset of action, duration, tolerability, dosage flexibility, patient support, and trust in regulated supply.

Another major shift is channel transformation. Telemedicine, online pharmacy verification, e-prescribing, and discreet home delivery have reduced barriers to consultation and refills. At the same time, regulators and manufacturers are under growing pressure to address counterfeit ED drugs, which are among the most commonly falsified medicines globally due to high demand, privacy concerns, and online purchasing behavior. The most competitive participants are combining clinical credibility, digital convenience, and supply-chain integrity.

Cumulative Impact of Artificial Intelligence on ED Drugs

Artificial intelligence is beginning to influence the erectile dysfunction drugs market across discovery, development, commercialization, and safety monitoring. In research and development, AI can help identify drug targets linked to nitric oxide signaling, endothelial function, hormonal pathways, and metabolic comorbidities. It can also support compound screening, trial design, patient stratification, and real-world evidence analysis, improving the efficiency of future ED therapies and combination approaches.

In commercial operations, AI-enabled platforms can personalize education, improve adherence reminders, support contraindication screening workflows, and route patients to appropriate clinician review. AI also strengthens pharmacovigilance by detecting adverse event signals in structured and unstructured data, and it can help identify suspicious online listings or abnormal distribution patterns linked to counterfeit products. The cumulative impact is not a replacement for clinician judgment but a more precise, safer, and more scalable ED care ecosystem.

Key Regional Insights: Asia-Pacific, North America, Europe, and Emerging Markets

Asia-Pacific is one of the most dynamic regions for erectile dysfunction drugs due to large male populations, rising diabetes and cardiovascular disease prevalence, expanding middle-class healthcare spending, and rapid adoption of telehealth in markets such as China, India, Japan, South Korea, and Australia. Regulatory diversity remains significant, but demand is reinforced by improving diagnosis rates, stronger domestic pharmaceutical manufacturing, and growing acceptance of men’s health consultations.

North America remains a mature and innovation-oriented region, supported by high awareness of PDE5 inhibitors, strong digital health infrastructure, and established prescription pathways in the United States and Canada. Latin America is benefiting from greater generic penetration and improving access through private pharmacies, with Brazil and Mexico serving as important demand centers. Europe is characterized by guideline-driven care, broad generic availability, strict pharmacovigilance standards, and increasing pharmacy and digital access models, particularly in large Western European markets.

The Middle East is seeing development through private healthcare investment, medical tourism, and increasing attention to lifestyle-related chronic disease, with GCC countries acting as higher-spending markets. Africa remains more uneven because of affordability constraints, underdiagnosis, and variable regulatory enforcement; however, urbanization, pharmacy expansion, and better chronic disease management are gradually improving access to regulated ED treatment.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining relevance as digital healthcare adoption, pharmacy modernization, and rising chronic disease prevalence increase demand for ED treatment, though affordability and regulatory enforcement vary widely by country. The GCC represents a premium access cluster where private healthcare, high diabetes prevalence, and consumer willingness to seek discreet men’s health solutions support demand for branded and high-quality generic products.

The European Union offers a regulated and guideline-centered environment in which generics, pharmacovigilance, and cross-border quality standards shape competition. BRICS economies collectively represent substantial patient-access opportunity because of large populations, expanding healthcare access, and a significant burden of diabetes and cardiovascular disease. Within this group, China, India, and Brazil are especially important for scale, while Russia and South Africa present more localized access, pricing, and regulatory dynamics.

G7 countries remain influential because they combine high purchasing power, mature regulatory systems, strong digital health adoption, and advanced clinical practice standards. NATO markets overlap heavily with North America and Europe, making them relevant for organizations prioritizing regulated supply chains, counterfeit prevention, and consistent quality assurance across allied high-income healthcare systems.

Key Country Insights for Major ED Drug Markets

The United States is a leading commercial environment for erectile dysfunction drugs due to high awareness, extensive telehealth prescribing, strong pharmacy infrastructure, and broad availability of generic sildenafil and tadalafil. Canada follows a regulated, access-focused model with strong clinician oversight, while Mexico combines private pharmacy access with growing demand for affordable generics. Brazil is Latin America’s key scale market, supported by a large population, expanding private healthcare use, and rising cardiometabolic disease burden.

In Europe, the United Kingdom is notable for pharmacy-led access pathways and strong online consultation models, while Germany and France emphasize regulated prescribing, reimbursement discipline, and high clinical standards. Italy and Spain show steady demand supported by aging populations and established urology care, while Russia remains a sizable but more complex market shaped by pricing, localization, and regulatory conditions.

China and India are central to future patient access because of large patient pools, increasing diagnosis, and expanding domestic pharmaceutical manufacturing. Japan’s market reflects high quality expectations, aging demographics, and physician-led care, while Australia combines strong regulation with digital health adoption. South Korea is supported by advanced healthcare infrastructure, strong pharmaceutical capabilities, and growing acceptance of men’s health treatment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically credible differentiation in a market where generic PDE5 inhibitors have changed price expectations. Organizations can compete through reliable quality, rapid and discreet access, patient education, contraindication screening support, and evidence-based positioning around onset, duration, tolerability, and dosing convenience.

Manufacturers, pharmacies, and digital health providers should invest in counterfeit prevention, verified online dispensing, serialization, and patient-facing authentication tools. Partnerships with urologists, primary care providers, cardiologists, diabetes clinics, and telehealth platforms can improve diagnosis and safe prescribing. Leaders should also build real-world evidence programs to understand adherence, switching behavior, adverse events, and patient-reported outcomes across age groups and comorbid populations.

Research Methodology

This executive summary is based on secondary research from established clinical, regulatory, and healthcare sources, including urology treatment guidelines, medicine labels, public regulatory databases, peer-reviewed literature on ED risk factors and PDE5 inhibitor use, and documented trends in telehealth, generic medicines, and pharmaceutical supply-chain quality.

The analysis applies a structured market framework covering therapy class, access channel, regional regulation, demand drivers, competitive intensity, and technology impact. Insights were validated through triangulation of clinical evidence, public health trends, regulatory positions, and observable commercial dynamics, with emphasis on verifiable facts rather than speculative market sizing.

Conclusion

The erectile dysfunction drugs market is mature in its core pharmacology but continues to evolve through access innovation, digital care, generic expansion, and stronger quality controls. PDE5 inhibitors remain the foundation of pharmacological ED treatment, while future industry development will depend on safer prescribing, better patient engagement, counterfeit mitigation, and integrated management of underlying cardiometabolic risk.

Organizations that combine evidence-based medicine with convenient, regulated, and patient-centered access will be best positioned to meet demand across established and emerging markets. The strongest opportunities are likely to come from trusted digital pathways, regional access strategies, real-world evidence, and differentiated services around men’s health rather than from price competition alone.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Erectile Dysfunction Drugs Market, by Treatment Duration
7.1. Long-Term
7.2. Short-Term
8. Erectile Dysfunction Drugs Market, by Dosage Strength
8.1. 100 Mg
8.2. 25 Mg
8.3. 50 Mg
9. Erectile Dysfunction Drugs Market, by Patient Age Group
9.1. 40-60 Years
9.2. 60+ Years
9.3. Under 40 Years
10. Erectile Dysfunction Drugs Market, by Drug Type
10.1. Sildenafil-based drugs
10.2. Tadalafil-based drugs
10.3. Vardenafil-based drugs
10.4. Avanafil-based drugs
10.5. Udenafil
11. Erectile Dysfunction Drugs Market, by Mode of Administration
11.1. Oral drugs
11.2. Injectable drugs
12. Erectile Dysfunction Drugs Market, by Distribution Channel
12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy
13. Asia-Pacific Erectile Dysfunction Drugs Market
14. North America Erectile Dysfunction Drugs Market
15. Latin America Erectile Dysfunction Drugs Market
16. Europe Erectile Dysfunction Drugs Market
17. Middle East Erectile Dysfunction Drugs Market
18. Africa Erectile Dysfunction Drugs Market
19. ASEAN Erectile Dysfunction Drugs Market
20. GCC Erectile Dysfunction Drugs Market
21. European Union Erectile Dysfunction Drugs Market
22. BRICS Erectile Dysfunction Drugs Market
23. G7 Erectile Dysfunction Drugs Market
24. NATO Erectile Dysfunction Drugs Market
25. United States Erectile Dysfunction Drugs Market
26. Canada Erectile Dysfunction Drugs Market
27. Mexico Erectile Dysfunction Drugs Market
28. Brazil Erectile Dysfunction Drugs Market
29. United Kingdom Erectile Dysfunction Drugs Market
30. Germany Erectile Dysfunction Drugs Market
31. France Erectile Dysfunction Drugs Market
32. Russia Erectile Dysfunction Drugs Market
33. Italy Erectile Dysfunction Drugs Market
34. Spain Erectile Dysfunction Drugs Market
35. China Erectile Dysfunction Drugs Market
36. India Erectile Dysfunction Drugs Market
37. Japan Erectile Dysfunction Drugs Market
38. Australia Erectile Dysfunction Drugs Market
39. South Korea Erectile Dysfunction Drugs Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Apricus Biosciences, Inc.
41.2. Aurobindo Pharma Limited
41.3. Auxilium Pharmaceuticals, Inc.
41.4. Bayer AG
41.5. Cipla Limited
41.6. Dong-A Pharmaceutical Co., Ltd.
41.7. Eli Lilly and Company
41.8. Endo International plc
41.9. Futura Medical plc
41.10. GlaxoSmithKline plc
41.11. Lupin Limited
41.12. Petros Pharmaceuticals Inc.
41.13. Pfizer Inc.
41.14. Sanofi S.A.
41.15. SK Chemicals Co., Ltd.
41.16. Sun Pharmaceutical Industries Ltd.
41.17. Teva Pharmaceutical Industries Ltd.
41.18. Viatris Inc.
41.19. Vivus Inc.
List of Figures
FIGURE 1. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL LONG-TERM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL LONG-TERM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL LONG-TERM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL SHORT-TERM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL SHORT-TERM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL SHORT-TERM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL 100 MG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL 100 MG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL 100 MG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL 25 MG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL 25 MG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL 25 MG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL 50 MG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL 50 MG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL 50 MG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL 40-60 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL 40-60 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL 40-60 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL 60+ YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL 60+ YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL 60+ YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL UNDER 40 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL UNDER 40 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL UNDER 40 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SILDENAFIL-BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL SILDENAFIL-BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL SILDENAFIL-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL TADALAFIL-BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL TADALAFIL-BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL TADALAFIL-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL VARDENAFIL-BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL VARDENAFIL-BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL VARDENAFIL-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL AVANAFIL-BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL AVANAFIL-BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL AVANAFIL-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL UDENAFIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL UDENAFIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL UDENAFIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ORAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ORAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 91. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 92. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 93. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 94. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 105. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 106. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 107. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 108. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 109. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 112. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 113. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 114. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 115. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 116. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 117. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 119. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 120. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 121. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 122. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 123. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 133. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 134. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 135. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 136. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 137. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 140. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 141. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 142. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 143. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 147. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 148. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 149. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 150. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 153. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 154. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 156. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 160. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 161. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 162. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 163. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 164. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 167. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 168. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 169. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 170. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 171. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 174. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 175. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 176. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 177. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 178. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 179. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 181. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 182. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 183. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 184. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 185. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 186. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 187. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 189. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 190. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 191. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 192. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 195. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 196. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 197. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 198. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 199. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 200. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 201. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 202. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 203. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 204. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 205. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 206. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 210. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 211. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 212. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 213. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 214. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 215. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 216. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 217. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 218. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 219. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 220. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 221. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 222. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 223. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 224. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 225. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 226. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 227. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 228. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 230. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 231. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 232. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 233. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 234. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 235. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 236. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 237. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 238. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 239. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 240. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 241. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 242. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 243. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 244. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 245. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 246. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 247. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 248. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 250. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 251. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
TABLE 252. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 253. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 254. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 255. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 256. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Erectile Dysfunction Drugs market report include:
  • Apricus Biosciences, Inc.
  • Aurobindo Pharma Limited
  • Auxilium Pharmaceuticals, Inc.
  • Bayer AG
  • Cipla Limited
  • Dong‑A Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Futura Medical plc
  • GlaxoSmithKline plc
  • Lupin Limited
  • Petros Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • SK Chemicals Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Vivus Inc.

Table Information

Report AttributeDetails
No. of Pages194
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.93 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.67 Billion
Compound Annual Growth Rate7.8%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Erectile Dysfunction Market - Global Forecast 2026-2032 - Product Image

Erectile Dysfunction Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Oral Medications for Erectile Dysfunction Market - Global Forecast 2025-2030 - Product Image

Oral Medications for Erectile Dysfunction Market - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Erectile Dysfunction Drugs - Global Strategic Business Report - Product Image

Erectile Dysfunction Drugs - Global Strategic Business Report

  • Report
  • 287 Pages
  • Global
From
Drugs for Erectile Dysfunction Market Report 2026 - Product Image

Drugs for Erectile Dysfunction Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Erectile Dysfunction - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Erectile Dysfunction - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Erectile Dysfunction Drug Market

The Erectile Dysfunction Drug market is a subset of the Sexual and Reproductive Health Drugs market. These drugs are used to treat erectile dysfunction, a condition in which a man is unable to achieve or maintain an erection sufficient for sexual intercourse. Common treatments include phosphodiesterase type 5 inhibitors, such as sildenafil, tadalafil, and vardenafil, as well as testosterone replacement therapy. These drugs are typically prescribed by a doctor and can be taken orally or injected directly into the penis. The Erectile Dysfunction Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Pfizer, Eli Lilly, Bayer, Merck, and GlaxoSmithKline. Other companies include Teva Pharmaceuticals, Sun Pharmaceuticals, and Cipla. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.